Cannabismarketcap

Jazz Pharmaceuticals (JAZZ) Earnings History

Latest Quarter: Q3 FY2026

Revenue
$1.24B
Net Income
-$483.4M
EPS
—
Gross Profit
—
Operating Cash Flow
$506.1M

Revenue Trend (Last 8 Quarters)

Q4 FY2024
$1.09B
Q1 FY2025
$897.8M
Q2 FY2025
$1.05B
Q3 FY2025
$1.13B
Q4 FY2025
$1.20B
Q1 FY2026
$1.07B
Q2 FY2026
$1.21B
Q3 FY2026
$1.24B

Net Income Trend (Last 8 Quarters)

Q4 FY2024
$191.1M
Q1 FY2025
-$92.5M
Q2 FY2025
-$718.5M
Q3 FY2025
$251.4M
Q4 FY2025
$203.5M
Q1 FY2026
$293.1M
Q2 FY2026
$192.8M
Q3 FY2026
-$483.4M

Full Earnings History

PeriodRevenueGross ProfitOp. IncomeNet IncomeEPSOCFFCFFiling Date
Q3 FY2026$1.24B$0-$413.4M-$483.4M—$506.1M$0—
Q2 FY2026$1.21B$0$248.2M$192.8M—$415.7M$0—
Q1 FY2026$1.07B$0$336.6M$293.1M—$408.2M$0—
Q4 FY2025$1.20B$0$254.6M$203.5M—$362.5M$0—
Q3 FY2025$1.13B$0$57.5M$251.4M—$474.7M$0—
Q2 FY2025$1.05B$0-$686.4M-$718.5M—$88.8M$0—
Q1 FY2025$897.8M$0-$55.9M-$92.5M—$429.8M$0—
Q4 FY2024$1.09B$0$190.8M$191.1M—$398.6M$0—
Q3 FY2024$1.05B$0$260.2M$215.1M—$398.7M$0—
Q2 FY2024$1.02B$0$199.4M$168.6M—$331.4M$0—
Q1 FY2024$902.0M$0$66.2M-$14.6M—$267.2M$0—
Q4 FY2023$1.01B$0$122.5M$94.2M—$167.3M$0—

Revenue Analysis

Revenue has grown for 2 consecutive quarters.The company generated $1.24B in revenue in Q3 FY2026, representing a +2.9% change from the prior quarter.

Over the last 8 reported quarters, JAZZ has generated between $897.8M and $1.24B in quarterly revenue.Gross profit is not broken out in JAZZ's most recent filing.

Profitability Analysis

Operating income for the quarter was -$413.4M, reflecting ongoing operational investments.

Net income came in at -$483.4M for the latest quarter. JAZZ is not yet profitable on a net income basis. The company reported an EPS of N/A for the period. Over the trailing 4 quarters, 3 out of 4 quarters were profitable.

Cash Flow Analysis

Jazz Pharmaceuticals generated $506.1M in operating cash flow during Q3 FY2026. Positive operating cash flow indicates the company is generating cash from its core business operations.

Free cash flow for the quarter was $0. The company may need to rely on external financing or existing cash reserves to fund growth initiatives. Across the last 4 quarters, cumulative operating cash flow was $1.69B.

Balance Sheet Snapshot (Q3 FY2026)

Total Assets$12.00B
Total Liabilities$0
Total Equity$4.19B
Cash & Equivalents$2.04B
Total Debt$5.57B

Frequently Asked Questions

What are Jazz Pharmaceuticals (JAZZ) earnings?+
Earnings refer to Jazz Pharmaceuticals's financial results reported each quarter, including revenue (total sales), net income (profit or loss after all expenses), earnings per share (EPS), and cash flow. These figures are filed with the SEC and provide investors with a snapshot of the company's financial health and operational performance.
When does JAZZ report earnings?+
Earnings filing dates for Jazz Pharmaceuticals are not yet available. Cannabis companies typically report quarterly earnings within 45 days of the fiscal quarter end. Check SEC filings for the most current schedule.
How do I read JAZZ's quarterly results?+
Start with revenue to understand total sales, then look at gross profit to see how much the company keeps after production costs. Operating income shows profitability from core operations, while net income reflects the bottom line after all expenses and taxes. EPS divides net income by shares outstanding, making it easier to compare across companies. Cash flow from operations shows actual cash generated by the business.
What do JAZZ's revenue and EPS numbers mean?+
Jazz Pharmaceuticals reported revenue of $1.24B and EPS of N/A in Q3 FY2026. Revenue measures total sales before any expenses, while EPS (earnings per share) divides net income by the number of outstanding shares. Negative EPS indicates the company reported a loss on a per-share basis.
How do earnings affect JAZZ's stock price?+
Earnings reports are one of the biggest catalysts for cannabis stock price movements. If JAZZ reports revenue or EPS above analyst expectations, the stock typically rises. If results disappoint, the stock may decline. The market also reacts to forward guidance, margin trends, and cash flow improvements. Cannabis stocks can be especially volatile around earnings due to lower liquidity and higher retail investor participation.
Is JAZZ profitable?+
Jazz Pharmaceuticals reported a net loss of -$483.4M in its most recent quarter (Q3 FY2026). Many cannabis companies are not yet profitable due to high operating costs, regulatory expenses, and the impact of IRS Section 280E on effective tax rates.
What is the difference between GAAP and non-GAAP earnings for cannabis companies?+
GAAP (Generally Accepted Accounting Principles) earnings follow standard accounting rules and include all expenses. Non-GAAP or "adjusted" earnings exclude one-time charges like impairments, restructuring costs, and stock-based compensation. Cannabis companies frequently report large non-cash impairments that can make GAAP results look worse than operational performance. Investors should review both metrics, but GAAP figures are what companies must file with the SEC.
How much cash does JAZZ have?+
As of Q3 FY2026, Jazz Pharmaceuticals reported cash and equivalents of $2.04B with total debt of $5.57B. Cash position is especially important for cannabis companies, as limited access to traditional banking and capital markets means companies must carefully manage their cash reserves.

More on JAZZ

JAZZ Overview
Live price, charts, and key metrics.
JAZZ Analysis
In-depth stock analysis and research.
JAZZ Financials
Revenue, earnings, and balance sheet.
JAZZ Forecast
Price targets and predictions.
JAZZ Chart
Interactive stock chart.

Disclaimer: The financial data presented on this page is sourced from publicly available SEC filings and is provided for informational purposes only. It should not be considered financial advice. Cannabismarketcap makes no guarantees about the accuracy or completeness of this data. Always consult official SEC filings and a qualified financial advisor before making investment decisions.